Australian shares are poised for a modest gain, contrasting with Wall Street's recent declines, as investors navigate global uncertainties and regional developments. In this context, penny stocks—often representing smaller or newer companies—offer intriguing opportunities for growth at accessible price points. Despite being an older term, these stocks can still hold significant potential when backed by strong financial health and solid fundamentals.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Financial Health Rating West African Resources (ASX:WAF) A$3.42 A$3.91B ★★★★★★ LaserBond (ASX:LBL) A$0.56 A$66.4M ★★★★★★ Regal Funds Management (ASX:RPL) A$2.53 A$930.38M ★★★★★★ Praemium (ASX:PPS) A$0.735 A$358.29M ★★★★★★ Ora Banda Mining (ASX:OBM) A$1.58 A$3.05B ★★★★★★ Australian Ethical Investment (ASX:AEF) A$4.87 A$554.35M ★★★★★★ EDU Holdings (ASX:EDU) A$0.885 A$109.86M ★★★★★★ Integrated Research (ASX:IRI) A$0.305 A$55.08M ★★★★★★ CTI Logistics (ASX:CLX) A$1.77 A$143.19M ★★★★☆☆ Cogstate (ASX:CGS) A$2.37 A$404.88M ★★★★★★

Click here to see the full list of 386 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Alcidion Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Alcidion Group Limited develops and licenses healthcare software products in Australia, New Zealand, and the United Kingdom, with a market cap of A$144.37 million.

Operations: The company generates revenue of A$48.62 million from its healthcare software solutions.

Market Cap: A$144.37M

Alcidion Group Limited, with a market cap of A$144.37 million and revenue of A$48.62 million, has recently become profitable, reporting net income of A$1.33 million for the half year ending December 2025. The company is debt-free and its short-term assets exceed liabilities, indicating solid financial health. Alcidion's management and board are experienced, contributing to strategic stability as they explore M&A opportunities selectively while focusing on growth pillars. Trading below analyst price targets suggests potential upside in stock value despite its low return on equity at 4.3%. Revenue guidance for 2026 exceeds A$50 million, reflecting positive momentum in sales growth.

Navigate through the intricacies of Alcidion Group with our comprehensive balance sheet health report here. Evaluate Alcidion Group's prospects by accessing our earnings growth report.ASX:ALC Financial Position Analysis as at Apr 2026

Cleo Diagnostics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cleo Diagnostics Ltd is a biotechnology company that develops and commercializes non-invasive blood tests for detecting ovarian cancer in Australia, with a market cap of A$86.22 million.

Story Continues

Operations: Cleo Diagnostics Ltd has not reported any specific revenue segments.

Market Cap: A$86.22M

Cleo Diagnostics Ltd, with a market cap of A$86.22 million, is pre-revenue but has seen significant revenue growth over the past year. Despite reporting a net loss of A$1.98 million for the half-year ending December 2025, the company remains debt-free and maintains sufficient cash runway for over three years based on current free cash flow. Its short-term assets significantly surpass liabilities, indicating strong liquidity management. The experienced management team and board provide strategic stability amid its unprofitable status and negative return on equity of -45.69%. Shareholder dilution has been minimal in recent times, maintaining investor confidence amidst its high volatility environment.

Click here and access our complete financial health analysis report to understand the dynamics of Cleo Diagnostics. Assess Cleo Diagnostics' previous results with our detailed historical performance reports.ASX:COV Financial Position Analysis as at Apr 2026

Kinatico

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Kinatico Ltd offers screening, verification, and SaaS-based workforce management and compliance technology systems in Australia and New Zealand, with a market cap of A$77.78 million.

Operations: The company generates revenue of A$34.60 million from providing screening and verification checks.

Market Cap: A$77.78M

Kinatico Ltd, with a market cap of A$77.78 million, has shown robust financial health and growth potential in the penny stock segment. The company reported half-year sales of A$17.63 million, reflecting a year-on-year increase from A$15.6 million and net income more than doubled to A$0.86 million compared to the previous year. Kinatico's earnings have grown significantly over the past year by 87.4%, outpacing industry averages, while maintaining profitability with no debt burden and improved profit margins at 4.5%. Analysts forecast continued earnings growth of 64% annually, suggesting strong future prospects for investors seeking high-growth opportunities within this sector.

Jump into the full analysis health report here for a deeper understanding of Kinatico. Understand Kinatico's earnings outlook by examining our growth report.ASX:KYP Financial Position Analysis as at Apr 2026

Next Steps

Reveal the 386 hidden gems among our  ASX Penny Stocks screener with a single click here. Contemplating Other Strategies? The end of cancer? These 31 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:ALC ASX:COV and ASX:KYP.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments